AFFILIATES TRANSACTIONS |
12 Months Ended |
|---|---|
Dec. 31, 2025 | |
| Related Party Transactions [Abstract] | |
| AFFILIATES TRANSACTIONS | NOTE 5 - AFFILIATES TRANSACTIONS
On October 25, 2024, the Company completed the acquisition of NDPD Pharma, Inc. (“NDPD”), an affiliate where the beneficial ownership includes the Company’s officers. The Company issued shares of Preferred Stock valued at $12,169,884 and shares of Common Stock valued at $289,774 in consideration for the Company officer’s ownership in NDPD, while shares of Preferred Stock valued at $7,148,346 were cancelled as the shares held by NDPD was returned to treasury. See also Note 6 – Business Combinations.
The Company holds a License Agreement (the “License” or “Agreement”) for a medical device (license obtained in 2019) with an affiliated company in which Company officers hold a majority interest. The device was developed prior to the establishment of Bioxytran. The maintenance cost for each license amounts to $5,000 yearly.
|